| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/25/2013 | CA2861339A1 Metalloenzyme inhibitor compounds |
| 07/25/2013 | CA2857346A1 1,5-naphthyridine derivatives and melk inhibitors containing the same |
| 07/25/2013 | CA2854093A1 3,5-disubstituted alkynylbenzene compound and salt thereof |
| 07/25/2013 | CA2851717A1 Anti-obesity potential of calebin a |
| 07/24/2013 | EP2617812A1 Composition for maintaining platelet function |
| 07/24/2013 | EP2617737A1 High purity heparin and production method therefor |
| 07/24/2013 | EP2617726A1 Diabetes therapeutic agent |
| 07/24/2013 | EP2617723A2 Novel compound acting as a cannabinoid receptor-1 inhibitor |
| 07/24/2013 | EP2617722A1 Hetero ring-fused imidazole derivative having ampk activating effect |
| 07/24/2013 | EP2617721A2 Novel heterocyclic compound, and composition for treating inflammatory diseases using same |
| 07/24/2013 | EP2617720A1 Novel cortistatin a analog and use thereof |
| 07/24/2013 | EP2617719A1 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 07/24/2013 | EP2617717A1 P2x4 receptor antagonist |
| 07/24/2013 | EP2617715A1 Glycine transporter inhibitor |
| 07/24/2013 | EP2617714A1 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
| 07/24/2013 | EP2617713A1 New Pharmaceutical Compounds |
| 07/24/2013 | EP2617711A1 Amino alcohol derivatives, salts thereof and immunosuppressive agents |
| 07/24/2013 | EP2617709A1 Guanidine derivatives as antiviral agents |
| 07/24/2013 | EP2617707A1 Novel compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient |
| 07/24/2013 | EP2617435A1 Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants |
| 07/24/2013 | EP2617433A2 Treatment of neurodegenerative diseases by targeting mirna |
| 07/24/2013 | EP2617429A1 Fat oxidation or energy metabolism enhancer |
| 07/24/2013 | EP2617426A1 Inhibitor of hmgb protein-mediated immune response activation, and screening method |
| 07/24/2013 | EP2617425A1 Pharmaceutical association for treating and/or preventing myoma and/or endometriosis, use of resveratrol and progestogen, pharmaceutical composition for treating and/or preventing myoma and/or endometriosis, medicament for treating and/or preventing myoma and/or endometriosis, kit and method for treating and/or preventing myoma and/or endometriosis |
| 07/24/2013 | EP2617424A2 Derivatives of uric and thiouric acid for oxidative stress-related diseases |
| 07/24/2013 | EP2617423A1 Purine derivatives for the treatment of cystic diseases |
| 07/24/2013 | EP2617422A1 Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| 07/24/2013 | EP2617421A1 Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| 07/24/2013 | EP2617420A1 Phenoxymethyl heterocyclic compounds |
| 07/24/2013 | EP2617419A1 Aza spiro alkane derivatives as inhibitors of metallproteases |
| 07/24/2013 | EP2617418A1 Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 07/24/2013 | EP2617417A1 Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 07/24/2013 | EP2617416A1 Cancer heat therapy-enhancing agent |
| 07/24/2013 | EP2617415A2 Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells |
| 07/24/2013 | EP2617414A2 Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| 07/24/2013 | EP2617411A1 Methods for the Treatment of Endometriosis |
| 07/24/2013 | EP2616543A1 MODIFIED iRNA AGENTS |
| 07/24/2013 | EP2616477A2 6-substituted demethyl-estradiol derivatives as er-beta agonists |
| 07/24/2013 | EP2616474A1 Novel antiviral acyclic nucleoside phosphonates |
| 07/24/2013 | EP2616470A1 Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| 07/24/2013 | EP2616469A1 Inhibitors of pi3k-delta and methods of their use and manufacture |
| 07/24/2013 | EP2616468A1 Fused heteroaryls and their uses |
| 07/24/2013 | EP2616467A1 Substituted azaindoles |
| 07/24/2013 | EP2616465A1 Triazine-oxadiazoles |
| 07/24/2013 | EP2616463A2 Preparation of crystalline bazedoxifene and its salts |
| 07/24/2013 | EP2616461A2 Potent and selective inhibitors of hepatitis c virus |
| 07/24/2013 | EP2616456A1 Nuclear export inhibitors |
| 07/24/2013 | EP2616451A1 Novel thiazol-carboximide derivatives as pdk1 inhibitors |
| 07/24/2013 | EP2616450A2 Sulfonamide compounds |
| 07/24/2013 | EP2616449A1 Anthraquinone compounds and their uses |
| 07/24/2013 | EP2616448A1 Substituted phenylacetate and phenylpropane amides and use thereof |
| 07/24/2013 | EP2616447A1 Pyrazine derivatives as enac blockers |
| 07/24/2013 | EP2616445A2 Estrogen receptor modulators and uses thereof |
| 07/24/2013 | EP2616444A2 Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction |
| 07/24/2013 | EP2616443A1 Phtalazine derivatives as jak1 inhibitors |
| 07/24/2013 | EP2616442A1 Inhibitors of pi3k-delta and methods of their use and manufacture |
| 07/24/2013 | EP2616441A2 Pyridine compounds and the uses thereof |
| 07/24/2013 | EP2616440A1 Arylosulfonamides for the treatment of cns diseases |
| 07/24/2013 | EP2616439A1 Tryptamine derivatives, their preparation and their use in gastropathy |
| 07/24/2013 | EP2616434A1 Prodrugs of guanfacine |
| 07/24/2013 | EP2616431A1 Novel cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof |
| 07/24/2013 | EP2616430A2 Novel phenoxyisobutyric acid compounds and methods for synthesis |
| 07/24/2013 | EP2616100A1 Compositions and methods for treatment of drug resistant multiple myeloma |
| 07/24/2013 | EP2616083A2 Removal of toxins from gastrointestinal fluids |
| 07/24/2013 | EP2616082A2 Methods and compositions for inhibiting autophagy for the treatment of fibrosis |
| 07/24/2013 | EP2616081A1 Method for mobilizing stem and/or progenitor cells |
| 07/24/2013 | EP2616080A1 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| 07/24/2013 | EP2616079A1 Treatment of bacterial infectious diseases |
| 07/24/2013 | EP2616078A1 Fulvestrant compositions and methods of use |
| 07/24/2013 | EP2616077A1 Anti-cancer activity of novel bicyclic heterocycles |
| 07/24/2013 | EP2616076A2 Pharmaceutical compositions |
| 07/24/2013 | EP2616075A1 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
| 07/24/2013 | EP2616074A1 Piperidinyl-substituted lactams as gpr119 modulators |
| 07/24/2013 | EP2616073A2 Inhibitors of viral entry into mammalian cells |
| 07/24/2013 | EP2616072A1 Azabenzothiazole compounds, compositions and methods of use |
| 07/24/2013 | EP2616071A2 Fatty acid synthase inhibitors |
| 07/24/2013 | EP2616070A1 Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors |
| 07/24/2013 | EP2616069A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol |
| 07/24/2013 | EP2616068A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for lowering intraocular pressure |
| 07/24/2013 | EP2616067A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating skin diseases and conditions |
| 07/24/2013 | EP2616066A1 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases |
| 07/24/2013 | EP2616065A1 Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy |
| 07/24/2013 | EP2616064A2 Ready to use ketorolac formulations |
| 07/24/2013 | EP2616063A1 Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| 07/24/2013 | EP2616062A1 Use of derivatives of pentaphyrine as antimicrobial and desinfectant agents |
| 07/24/2013 | EP2616061A2 Formulations for treatment with glucosinolate |
| 07/24/2013 | EP2616060A1 Compositions of abscisic acid for animal health |
| 07/24/2013 | EP2616059A2 Pharmaceutical and nutraceutical compositions of abscisic acid |
| 07/24/2013 | EP2616058A1 Animal feed compositions of abscisic acid |
| 07/24/2013 | EP2616057A2 Combination of braf and vegf inhibitors |
| 07/24/2013 | EP2616056A1 Terpenoid analogues and uses thereof for treating neurological conditions |
| 07/24/2013 | EP2616055A1 Compositions for treating cancer treatment - related fatigue |
| 07/24/2013 | EP2616054A2 Therapy for mll-rearranged leukemia |
| 07/24/2013 | EP2616053A2 Pharmaceutical compositions of curcumin |
| 07/24/2013 | EP2616052A1 Methods, compounds and compositions relating to activating a latent virus |
| 07/24/2013 | EP2616048A1 Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
| 07/24/2013 | EP2616047A2 Non-aqueous oily injectable formulation exhibiting preservative efficacy |
| 07/24/2013 | EP2616046A1 Aqueous drug delivery system comprising off - flavor masking agent |
| 07/24/2013 | EP2616044A1 Pharmaceutical composition |
| 07/24/2013 | EP2615931A1 Methods of reducing blood lactate concentration |